Table 1. Patient characteristics and... | American Society of Hematology

Table 1.

Patient characteristics and outcomes

Patient no.	Age, y	Diagnosis	Time since diagnosis	Risk factors leading to inclusion	Status at transplantation*	Relapse	Therapy of relapse	Follow-up, d	Status of disease*	Cause of death
1	42	CML	5 y	Autograft	1 CP	No	—	232	Dead	IFI
2	48	AML	2 y	Pulmonary aspergillosis, hepatotoxicity	2 CR	No	—	1018	CR	NA
3	56	MDS	6 mo	MUD and age	RAEB	No	—	1011	CR	NA
4	59	CML	3 y	Hepatotoxicity	1 CP	D 56	DLI	899	CR	NA
5	49	CML	4 y	Reduced lung diffusion capacity	1 CP	D 430	DLI	853	CR	NA
6	52	CML	5 y	MUD and age	1 CP	No	—	807	CR	NA
7	27	MDS	2 mo	Hepatotoxicity, preceeding ATG and CSA therapy for suspected SAA	Hypoplastic	No	—	796	CR	NA
8	48	MM	4 mo	Autograft, amyloidosis	1 PR	No	—	62	Dead	Amyloidosis
9	52	MM	4 y	Amyloidosis	2 PR	No	—	722	CR	NA
10	60	CML	5 y	Autograft	1 CP	D 163	RI	709	CR	NA
11	38	CML	9 y	Hepatotoxicity, reduced lung diffusion capacity	2 CP	No	—	695	BP after graft failure	NA
12	20	AML	3 y	2 allografts	3 CR	No	—	673	CR	NA
13	50	CLL	1 y	Reduced lung diffusion capacity	1 PR	No	—	668	CR	NA
14	58	AML	6 mo	Reduced lung diffusion capacity	1 CR	No	—	661	CR	NA
15	57	sAML	9 mo	MUD and age	2 PR	No	—	112	Dead	Infection
16	50	FLC	2.5 y	MUD and age, previous toxic colitis	2 CR	No	—	631	CR	NA
17	28	sAML	7 mo	Hepatotoxicity, previous chemotherapy for germ cell tumor	1 relapse	NE	—	29	Dead	Infection
18	57	CLL	4 y	MUD and age	1 PR	Progression D 90	DLI + CX	547	CR	NA
19	53	AML	11 mo	MUD and age	1 relapse	D 325	CX + ReTX	520	CR	NA
20	48	MM	8 mo	Autograft	1 PR	No, but aneuploid plasma cells	RI	498	CR	NA
21	50	MM	2.75 y	Autograft, MUD and age	4 PR	No	—	477	CR	NA
22	52	FLC	2 y	MUD and age	2 CR	No	—	470	CR	NA
23	49	MDS	8 mo	Hepatotoxicity, reduced lung diffusion capacity	RAEB	No	—	146	Dead	IFI
24	43	T-cell NHL	13 mo	Pulmonary aspergillosis	2 PR	No	—	87	Dead	Infection
25	40	FLC	10 mo	Hepaotoxicity	Refractory	No	—	331	CR	NA
26	40	Diffuse large-cell NHL	12 mo	Autograft	1 CR	D 113	CX	371	Dead	Relapse
27	38	CLL	10 mo	Hepatotoxicity, latent toxoplasmosis and chronic tonsillitis	1 CR	Persistence D 56	RI	311	CR	NA
28	48	CLL	6 y	Heptatotoxicity, colitis ulcerosa	2 relapse	Graft failure D45	—	226	CR after 2 TX	NA
29	41	AML	2 mo	Fungal pneumonia, incomplete regeneration after induction chemotherapy	1 PR	D 101	CX	186	Dead	Relapse
30	58	MM	5 y	Autograft	PD	No	—	247	CR	NA

Patient no.	Age, y	Diagnosis	Time since diagnosis	Risk factors leading to inclusion	Status at transplantation*	Relapse	Therapy of relapse	Follow-up, d	Status of disease*	Cause of death
1	42	CML	5 y	Autograft	1 CP	No	—	232	Dead	IFI
2	48	AML	2 y	Pulmonary aspergillosis, hepatotoxicity	2 CR	No	—	1018	CR	NA
3	56	MDS	6 mo	MUD and age	RAEB	No	—	1011	CR	NA
4	59	CML	3 y	Hepatotoxicity	1 CP	D 56	DLI	899	CR	NA
5	49	CML	4 y	Reduced lung diffusion capacity	1 CP	D 430	DLI	853	CR	NA
6	52	CML	5 y	MUD and age	1 CP	No	—	807	CR	NA
7	27	MDS	2 mo	Hepatotoxicity, preceeding ATG and CSA therapy for suspected SAA	Hypoplastic	No	—	796	CR	NA
8	48	MM	4 mo	Autograft, amyloidosis	1 PR	No	—	62	Dead	Amyloidosis
9	52	MM	4 y	Amyloidosis	2 PR	No	—	722	CR	NA
10	60	CML	5 y	Autograft	1 CP	D 163	RI	709	CR	NA
11	38	CML	9 y	Hepatotoxicity, reduced lung diffusion capacity	2 CP	No	—	695	BP after graft failure	NA
12	20	AML	3 y	2 allografts	3 CR	No	—	673	CR	NA
13	50	CLL	1 y	Reduced lung diffusion capacity	1 PR	No	—	668	CR	NA
14	58	AML	6 mo	Reduced lung diffusion capacity	1 CR	No	—	661	CR	NA
15	57	sAML	9 mo	MUD and age	2 PR	No	—	112	Dead	Infection
16	50	FLC	2.5 y	MUD and age, previous toxic colitis	2 CR	No	—	631	CR	NA
17	28	sAML	7 mo	Hepatotoxicity, previous chemotherapy for germ cell tumor	1 relapse	NE	—	29	Dead	Infection
18	57	CLL	4 y	MUD and age	1 PR	Progression D 90	DLI + CX	547	CR	NA
19	53	AML	11 mo	MUD and age	1 relapse	D 325	CX + ReTX	520	CR	NA
20	48	MM	8 mo	Autograft	1 PR	No, but aneuploid plasma cells	RI	498	CR	NA
21	50	MM	2.75 y	Autograft, MUD and age	4 PR	No	—	477	CR	NA
22	52	FLC	2 y	MUD and age	2 CR	No	—	470	CR	NA
23	49	MDS	8 mo	Hepatotoxicity, reduced lung diffusion capacity	RAEB	No	—	146	Dead	IFI
24	43	T-cell NHL	13 mo	Pulmonary aspergillosis	2 PR	No	—	87	Dead	Infection
25	40	FLC	10 mo	Hepaotoxicity	Refractory	No	—	331	CR	NA
26	40	Diffuse large-cell NHL	12 mo	Autograft	1 CR	D 113	CX	371	Dead	Relapse
27	38	CLL	10 mo	Hepatotoxicity, latent toxoplasmosis and chronic tonsillitis	1 CR	Persistence D 56	RI	311	CR	NA
28	48	CLL	6 y	Heptatotoxicity, colitis ulcerosa	2 relapse	Graft failure D45	—	226	CR after 2 TX	NA
29	41	AML	2 mo	Fungal pneumonia, incomplete regeneration after induction chemotherapy	1 PR	D 101	CX	186	Dead	Relapse
30	58	MM	5 y	Autograft	PD	No	—	247	CR	NA

CML indicates chronic myeloid leukemia; CP, chronic phase, —, none; IFI, invasive fungal infection; AML, acute myeloid leukemia; CR, complete remission; NA, not applicable; MDS, myelodysplastic syndrome; MUD, matched unrelated donor; RAEB, refractory anemia with excess of blasts; ATG, antithymocyte globulin; SAA, severe aplastic anemia; DLI, donor lymphocyte infusion; MM, multiple myeloma; PR, partial remission; BP, blastic phase; CLL, chronic lymphocytic leukemia; sAML, secondary acute myeloid leukemia; FLC, follicular center lymphoma; NE, not evaluable; CX, chemotherapy; TX, allogeneic hematopoietic stem cell transplantation; ReTX, retransplantation; RI, reduction of immunosuppression; T-cell NHL, T-cell non-Hodgkin lymphoma; NHL, non-Hodgkin lymphoma; and PD, progressive disease.

1 indicates first; 2, second; and 3, third.

View Large

This Feature Is Available To Subscribers Only